| Identification | More | [Name]
Terazosin | [CAS]
63590-64-7 | [Synonyms]
1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-[(TETRAHYDRO-2-FURANYL)CARBONXYL]PIPERAZINE, HYDROCHLORIDE
1-[4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL]-4-([TETRAHYDRO-2-FURANYL]CARBONYL) PIPERAZINE HYDROCHLORIDE
[4-(4-AMINO-6,7-DIMETHOXY-QUINAZOLIN-2-YL)PIPERAZIN-1-YL]-OXOLAN-2-YL-METHANONE
HYTRIN
TERAZOSIN HCL
TERAZOSIN HYDROCHLORIDE
TERAZOSIN MONOHYDROCHLORIDE
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)p
arbonyl)-
terazosine
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonxyl]piperazine, Hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-(9CI)
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine
Terazosin
N-(2-tertrahydrofuroyl)-piperazine
1-(4-Amino-6，7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbowl]piperazine
Hytrin：Hytrinex
Urodie
Vasomet：Vicard | [EINECS(EC#)]
613-265-8 | [Molecular Formula]
C19H25N5O4 | [MDL Number]
MFCD00467965 | [Molecular Weight]
387.43 | [MOL File]
63590-64-7.mol |
| Chemical Properties | Back Directory | [Appearance]
White to Off-White Crystalline Powder | [Melting point ]
281-283°C | [Boiling point ]
664.5±65.0 °C(Predicted) | [density ]
1.332±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
H2O: 25 mg/mL
| [form ]
powder
| [pka]
pKa (0.1N NaOH): 7.1(at 25℃) | [color ]
white to off-white
| [Water Solubility ]
30.6mg/L(22.5 ºC) | [Usage]
An a-1-adrenergicblocker related to prazosin | [BCS Class]
1/3 | [InChIKey]
VCKUSRYTPJJLNI-UHFFFAOYSA-N | [CAS DataBase Reference]
63590-64-7(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,Xi | [Risk Statements ]
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [RTECS ]
TK8044925
|
| Hazard Information | Back Directory | [Chemical Properties]
White to Off-White Crystalline Powder | [Uses]
An a-1-adrenergicblocker related to prazosin | [Uses]
An α-1-adrenergicblocker related to prazosin. | [Uses]
Terazosin is used for the same indications as is prazosin; however, it has the advantage of
being able to be used once a day. | [Definition]
ChEBI: Terazosin is a member of quinazolines, a member of piperazines, a member of furans and a primary amino compound. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist. | [Clinical Use]
Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH) | [Synthesis]
Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-
piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a
tetrahydrofuryl radical. It is synthesized in exactly the same manner except using
1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51]. | [Drug interactions]
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect - avoid concomitant use.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect; increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect; increased
risk of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension
when used in combination. | [Metabolism]
Terazosin is metabolised in the liver; one of the
metabolites has antihypertensive activity.
Terazosin is excreted in faeces via the bile, and in the
urine, as unchanged drug and metabolites. | [storage]
Store at -20°C |
|
|